Why Women Over 40 Ask This Differently
Perimenopause/menopause shifts, slower recovery, insulin resistance, appetite dysregulation, rising cholesterol, old strategies stopped working.
Comparison Table
| Option | Best for | Main tradeoff |
|---|---|---|
| Wegovy/semaglutide | Mainstream familiarity, strong data | Expensive without coverage |
| Zepbound/tirzepatide | Strongest efficacy ceiling | Pricier, insurance-dependent |
| Compounded semaglutide | Cash-pay budget | Different regulatory category |
| Compounded tirzepatide | Stronger upside, cash-pay | More expensive than compounded sema |
| Insurance-first programs | Strong commercial insurance | Approval can be slow |
FAQ
Is tirzepatide better than semaglutide for women over 40? Often viewed as stronger, but stronger doesn’t mean better for everyone.
The FDA has proposed excluding semaglutide and liraglutide from the 503B bulk compounding list, with public comments open through June 29, 2026. If finalized, this could affect the availability, pricing, and continuity of some compounded GLP-1 programs. We will update this page as the regulatory situation develops.
Are GLP-1s safe for women over 40? Depends on health history. Clinician evaluation required.
What if I’m in perimenopause? One reason many women explore GLP-1s when weight gain feels resistant to diet/exercise.
Is the cheapest option the worst? Not necessarily. Lower-cost paths involve different tradeoffs.
Insurance coverage for GLP-1 medications varies widely by plan, provider, and medication type. Coverage is not guaranteed.
Pricing last verified: April 2026. GLP-1 telehealth pricing changes frequently — always confirm current rates on each provider’s website.
Related Reading
RangeYourself is reader-supported. We may earn a commission when you click on certain links — at no extra cost to you. Editorial recommendations are made independently. Last reviewed April 30, 2026.
